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Abstract
Inbred mice are the mainstay for preclinical cancer assessment of potential therapeutics, especially immune-based
approaches. However, the use of young, lean, inbred mice housed under specific-pathogen-free conditions does
not mirror the human cancer scenario. This commentary discusses some of the issues in evaluating
immunotherapeutics in mice given recent advances.
Main text
Immunotherapy is now at the forefront of cancer therap-
ies with an increasing assortment of approaches being
evaluated (ie checkpoint blockade, oncolytic viruses,
chimeric antigen receptor (CAR) T and NK cells as well
as dendritic cell vaccines and other immunostimulatory
regimens alone or in combination). In addition, im-
munotherapy combined with radiation therapy and even
chemotherapeutics have resulted in increased efficacy
[1, 2] indicating that these combinations will also be
increasingly applied. Given the increased potential of sig-
nificant off-target toxicities arising (ie cytokine storm from
the therapy, tumor lysis syndrome, autoimmune attack of
normal cell-types) as well as the numerous factors that
can impact efficacy, it is critical that preclinical models be
used that can mirror the current human cancer scenario.
Immunotherapy stands out as a regimen where a major
variable is not only the cancer (as with radiation and
chemotherapy application), but the patient’s own immune
system and responsiveness, which is not always predict-
able, dynamic and is not easily assessed. Additionally, des-
pite recent successes, many critical questions still remain:
why do some patients respond and not others? Can the re-
sponses be sustained and amplified? What are potentially
predictive surrogate markers for both responses and
recurrence? What toxicities can be predicted and pre-
emptively targeted? What is the best preclinical model to
assess? Most of these questions revolve around the dy-
namics of immune system, which is constantly evolving in
every individual. What makes immunotherapy also stand
out (both in positive and negative ways) from other con-
ventional cytoreductive therapies is the potential for con-
tinuous and sustained (if not amplified) responses after
treatment.
Currently, the inbred mouse is by far the most com-
monly used preclinical model in cancer and it is growing
in use, in part through the generation of genetically
engineered mouse models (GEMM) that allow for spon-
taneous tumor generation rather than simple transfer of
fully transformed and extensively cultured, mouse tumor
lines into normal healthy young mice (although for
treatment studies, transfer of the tumor lines are still
predominantly used). It must be acknowledged immedi-
ately that critical discoveries, particularly in cancer im-
munotherapy, have been brought to clinical practice
using this model. The basic characterizations of immune
cells/pathways as well as fundamental principles in
tumor progression and evasion (including multiple ap-
proaches in immune-targeted attack of the cancer) have
all been borne out using these models. The issues arise
when attempting to dig further and optimize these ap-
proaches and assess long-term impact. Importantly, the
vast majority of preclinical mouse studies use relatively
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young (8–12 week old) healthy inbred mice; predomin-
antly female (due to ease in housing) and housed under
strict specific pathogen free (SPF) conditions. Therein
resides the paradox of attempting to mirror the human
clinical scenario using mice under these conditions. We
have recently demonstrated that other variables such age
and obesity can markedly impact outcome after adminis-
tration of systemic immunotherapy in mice where young
mice can tolerate regimens that are quickly lethal for
aged or obese mice [3, 4]. Despite the fact that cancer is
considered a disease of the aged (over the age 55 is me-
dian time for diagnosis in U.S.) and obesity in the U.S. is
reaching epic proportions, it is surprisingly difficult to
perform studies using aged and obese mice due to cost,
time and accessibility. These mice are very expensive
and time-consuming to generate in-house and, unless
one has a grant from the National Institute on Aging
(NIA), extremely difficult to obtain in sufficient numbers
to perform efficacy studies. Obtaining these mice from
commercial vendors can also be highly costly and unpre-
dictable to impossible. Combine these issues with the in-
herent cost of performing long-term efficacy studies due
to the need for larger sample size and the new NIH
mandate to assess effects in both sexes, it is perhaps no
wonder there is a paucity of literature assessing the im-
pact of age and obesity on cancer progression and ther-
apy outcome in mice despite the fact these factors
predominate clinical cancer patients. There are even less
studies assessing toxicities that can arise from the differ-
ent therapies despite the fact these are growing both in
incidence and severity in the clinic. Another key issue
that further complicates mouse studies is the micro-
biome and impact of housing conditions on the immune
response. Recent studies have clearly demonstrated the
dramatic impact of the microbiome, not only immuno-
therapy but also on chemotherapeutic responses in mice
[5–7]. These studies also demonstrate a critical issue in
using inbred mice: microbiome variability between ven-
dors and even institutional colonies can lead to false-
positive or false-negative results in immunotherapy or
even tumor growth using the same genetic strain. The
microbiome variable may also account for differences in
data and lack of reproducibility between laboratories be-
ing observed. Aging and obesity also impact the micro-
biome although these studies are even more preliminary.
The NIH has implemented new guidelines for reagent
authentication yet the emphasis has been on cell lines
and reagents and not mice (other than assessment of
both sexes unless justified). Genetic drift among mouse
colonies is well-accepted but microbiome differences
also influence differences in immune therapy outcomes
using the same inbred strain, particularly when mice
housed under SPF conditions are used. While SPF col-
onies have led to marked improvements in maintaining
breeding colonies and reducing animal costs, it also has
a tremendous impact on immune development, leading
to an experimental model system which is even more re-
mote immunologically from the human scenario. This
has recently been dramatically brought to light immuno-
logically comparing inbred mice housed under SPF con-
ditions to conventionally-housed store-bought mice and
even feral mice in which marked effects were observed
[8]. Human exposure to pathogens throughout life all
contribute to the immune fingerprint that is unique to
the individual and that becomes even more fixed with
normal aging and thymic involution. Additionally, latent
infections that permeate the majority of the human
population such CMV and EBV markedly impact T-cell
function and result in significant skewing of the reper-
toire with aging. All of these effects result in an immune
phenotype dramatically different from a young SPF
inbred mouse. Xenograft studies using human immune
cells in immunodeficient mice fare no better due to
species-specific properties of key cytokines/factors
(interferon-gamma and GM-CSF come to mind) and
MHC divergence; which are critical for immune devel-
opment, as well as potential for xenoreactivity and donor
variability make such studies difficult to reproduce and
clinically extrapolate. To better emulate the human clin-
ical situation and the impact it will have on immuno-
therapy outcome, it will be necessary to perform studies
in conventionally housed mice (it is of interest that once
animal colonies became SPF in the 1980′s, graft-versus-
host disease models became very difficult to repeat from
earlier studies, an observation illustrating the impact of
the environment on disease pathobiology). Ironically, it is
currently exceedingly difficult to obtain and study either
feral mice or even mice housed under conventional condi-
tions due to common restrictions in place at the vast ma-
jority of SPF colonies. When attempting to assess effects
of immunotherapeutic interventions, young lean mice
kept under SPF conditions are far removed immunologic-
ally from the aged, obese cancer patient that has been ex-
posed to a world full of pathogens over a lifespan. These
epigenetic and environmental factors critically need to be
incorporated into preclinical cancer models, especially
when evaluating immune therapeutics. Using an inappro-
priate model can dramatically under or over-estimate effi-
cacy as well as toxicities and mislead physicians when they
try to apply the lessons learned in the laboratory.
If, as it seems, immunotherapy is going to become a
mainstay of cancer treatment and be applied with other
regimens or in combinations, it is absolutely imperative
that the mouse modeling better reflect the dynamic hu-
man host-tumor relationship and immune phenotype.
The genetic differences between mouse and man are a
formidable barrier not easily circumvented but not in-
cluding these other non-genetic variables (ie age, obesity,
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use of non-SPF housing conditions) only increases the
magnitude of the barrier. NIH needs to provide funding
resources encouraging more accessibility as well as
optimization of such models as this crosses the different
NIH institutes since immune/inflammatory pathways
permeate almost every pathological condition. Such an
approach will certainly increase the costs of doing re-
search; however, clinically applicable research findings
will spare patients enormous harm and costs from test-
ing interventions that won’t help them and could pos-
sibly hurt them. Which cost is greater?
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